Champions Oncology (NASDAQ:CSBR) Releases Quarterly Earnings Results, Meets Expectations

Champions Oncology (NASDAQ:CSBR) posted its earnings results on Monday. The biotechnology company reported ($0.05) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.05), Zacks reports. Champions Oncology had a negative return on equity of 57.31% and a negative net margin of 3.94%.

Champions Oncology Stock Performance

NASDAQ:CSBR traded down $0.05 during mid-day trading on Monday, hitting $6.08. 6,713 shares of the company’s stock traded hands, compared to its average volume of 7,784. The company has a market capitalization of $84.45 million, a P/E ratio of -38.00 and a beta of 0.39. The company has a fifty day moving average of $6.06 and a 200 day moving average of $6.19. Champions Oncology has a twelve month low of $5.50 and a twelve month high of $8.74.

Analyst Ratings Changes

Separately, Weiss Ratings cut shares of Champions Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 30th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Champions Oncology currently has a consensus rating of “Sell”.

Hedge Funds Weigh In On Champions Oncology

Several hedge funds and other institutional investors have recently modified their holdings of the stock. XTX Topco Ltd purchased a new stake in Champions Oncology during the 2nd quarter worth approximately $103,000. Essex Investment Management Co. LLC acquired a new stake in shares of Champions Oncology during the fourth quarter worth $126,000. Jane Street Group LLC acquired a new stake in shares of Champions Oncology during the first quarter worth $200,000. Goldman Sachs Group Inc. purchased a new stake in shares of Champions Oncology during the first quarter valued at $201,000. Finally, Acadian Asset Management LLC grew its holdings in shares of Champions Oncology by 28.7% during the first quarter. Acadian Asset Management LLC now owns 39,511 shares of the biotechnology company’s stock valued at $341,000 after buying an additional 8,814 shares during the last quarter. 41.30% of the stock is owned by hedge funds and other institutional investors.

About Champions Oncology

Champions Oncology, Inc engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients.